A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation
Bortezomib can be combined with lenalidomide in patients with AML and MDS relapsing after HCT with overall 19 % of patients achieving composite remission. Toxicity was manageable and primarily related to cytopenias during induction. Responding patients included 1 with NPM1-mutated AML as well as 2 harboring TP53 gene mutations, suggesting possible therapeutic benefit in very high-risk disease. Bortezomib and lenalidomide could be safely used following donor lymphocyte infusion without evidence of graft failure or immune-related toxicity.
Authors
- Philip C. Amrein (ORCID: https://orcid.org/0000-0001-7770-2623)
- Andrew Mark Brunner (ORCID: https://orcid.org/0000-0002-2169-4115)
- Yi‐Bin Chen (ORCID: https://orcid.org/0000-0002-9554-1058)
- Thomas R. Spitzer (ORCID: https://orcid.org/0000-0003-1384-5742)
- Karen K. Ballen (ORCID: https://orcid.org/0000-0003-1706-3975)
- Jacalyn Rosenblatt (ORCID: https://orcid.org/0000-0001-5582-8161)
- Christine Connolly
- Brandon J. Aubrey (ORCID: https://orcid.org/0000-0002-1372-3107)
- Gabriela Hobbs (ORCID: https://orcid.org/0000-0002-0199-9333)
- Malgorzata McMasters
- Traci M. Blonquist (ORCID: https://orcid.org/0000-0003-1346-988X)
- Areej El‐Jawahri (ORCID: https://orcid.org/0000-0002-3556-1495)
- Amir T. Fathi (ORCID: https://orcid.org/0000-0002-5848-6221)
- Emma Logan
- Aura Y. Ramos
- Steven L. McAfee
- David Avigan
- Bimalangshu R. Dey
Institutions
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- University of Virginia (US)
Publication Details
- Journal
- Leukemia Research
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1016/j.leukres.2025.107693
- Citations
- 2
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Celgene
- Takeda Pharmaceutical Company
- Edward P. Evans Foundation